-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tipifarnib in Anaplastic Large Cell Lymphoma (ALCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tipifarnib in Anaplastic Large Cell Lymphoma (ALCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tipifarnib in Anaplastic Large Cell Lymphoma (ALCL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATI-2173 in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATI-2173 in Hepatitis B report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATI-2138 in Inflammatory Bowel Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ATI-2138 in Inflammatory Bowel Disease Drug Details: ATI-2138 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanidatamab in Extrahepatic Bile Duct Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zanidatamab in Extrahepatic Bile Duct Cancer Drug Details: Zanidatamab is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Docetaxel in Prostate Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Docetaxel in Prostate Cancer Drug Details: docetaxel (ATI-1123) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Etrumadenant in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Etrumadenant in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Etrumadenant in Bladder Cancer Drug Details: AB-928 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Metronidazole in Clostridioides difficile Infections (Clostridium difficile Associated Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Metronidazole in Clostridioides difficile Infections (Clostridium difficile Associated Disease) report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zunsemetinib in Psoriatic Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zunsemetinib in Psoriatic Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Zunsemetinib in Psoriatic Arthritis Drug Details:Zunsemetinib (ATI-450, CDD-450) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zunsemetinib in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zunsemetinib in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zunsemetinib in Rheumatoid Arthritis Drug Details: Zunsemetinib (ATI-450, CDD-450) is under development...